FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103546390> ?p ?o ?g. }

• W2103546390 endingPage "S18" @default.
• W2103546390 startingPage "S15" @default.
• W2103546390 abstract "We compared the efficacy and safety of the oral aromatase inactivator exemestane (EXE) with megestrol acetate (MA) in women with metastatic breast cancer. This phase III randomized, double-blind, multicenter study was conducted in 769 postmenopausal women who had experienced tamoxifen failure. Treatment arms consisted of EXE 25 mg once daily (n = 366) or MA 40 mg four times daily (160 mg daily; n = 403). Peerreviewed, intent-to-treat analyses demonstrated that EXE induced a trend toward higher rates of complete response (CR) + partial response (PR) (15.0% vs. 12.4%) and of CR + PR + stable disease (SD) ≥ 24 weeks (37.4% vs. 34.6%), but differences were not statistically significant. Statistically significant differences favoring EXE were seen in median duration of CR + PR + SD ≥ 24 weeks (60.1 vs. 49.1 weeks; P = 0.025), time to tumor progression (20.3 vs. 16.6 weeks; P = 0.037), time to treatment failure (16.3 vs. 15.7 weeks; P = 0.042), and overall survival (not reached vs. 123.4 weeks; P = 0.039). Both treatments were well tolerated, but MA was associated with more grade 3 or 4 weight gain (8% vs. 17%, P = 0.001); the pain score was similar in both groups. There was a trend toward superiority in treatment-related signs and symptoms (TRSS) with EXE. There was greater improvement in the pain score and TRSS in patients achieving an objective response with EXE vs. MA. Quality of life improved or was similar for EXE in most domains. Exemestane offers an important new treatment option for postmenopausal women with hormone-responsive breast cancer." @default.
• W2103546390 created "2016-06-24" @default.
• W2103546390 creator A5002951950 @default.
• W2103546390 creator A5007869975 @default.
• W2103546390 creator A5022173747 @default.
• W2103546390 creator A5032213495 @default.
• W2103546390 creator A5035387502 @default.
• W2103546390 creator A5045380644 @default.
• W2103546390 creator A5046939478 @default.
• W2103546390 creator A5060759473 @default.
• W2103546390 creator A5062388816 @default.
• W2103546390 creator A5066010864 @default.
• W2103546390 creator A5068970824 @default.
• W2103546390 creator A5070704228 @default.
• W2103546390 creator A5070860465 @default.
• W2103546390 creator A5072030442 @default.
• W2103546390 creator A5075821880 @default.
• W2103546390 creator A5081094525 @default.
• W2103546390 creator A5083634538 @default.
• W2103546390 date "2000-09-01" @default.
• W2103546390 modified "2023-10-12" @default.
• W2103546390 title "Exemestane Improves Survival in Metastatic Breast Cancer: Results of a Phase III Randomized Study" @default.
• W2103546390 cites W1909697168 @default.
• W2103546390 cites W1929731168 @default.
• W2103546390 cites W1934173384 @default.
• W2103546390 cites W1975705936 @default.
• W2103546390 cites W1985104230 @default.
• W2103546390 cites W1994207027 @default.
• W2103546390 cites W2040935785 @default.
• W2103546390 cites W2042041418 @default.
• W2103546390 cites W2105913824 @default.
• W2103546390 cites W2137892274 @default.
• W2103546390 cites W2146049019 @default.
• W2103546390 cites W2176579253 @default.
• W2103546390 cites W2202169216 @default.
• W2103546390 cites W4230686738 @default.
• W2103546390 doi "https://doi.org/10.3816/cbc.2000.s.003" @default.
• W2103546390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11970744" @default.
• W2103546390 hasPublicationYear "2000" @default.
• W2103546390 type Work @default.
• W2103546390 sameAs 2103546390 @default.
• W2103546390 citedByCount "20" @default.
• W2103546390 countsByYear W21035463902012 @default.
• W2103546390 countsByYear W21035463902016 @default.
• W2103546390 countsByYear W21035463902018 @default.
• W2103546390 countsByYear W21035463902022 @default.
• W2103546390 crossrefType "journal-article" @default.
• W2103546390 hasAuthorship W2103546390A5002951950 @default.
• W2103546390 hasAuthorship W2103546390A5007869975 @default.
• W2103546390 hasAuthorship W2103546390A5022173747 @default.
• W2103546390 hasAuthorship W2103546390A5032213495 @default.
• W2103546390 hasAuthorship W2103546390A5035387502 @default.
• W2103546390 hasAuthorship W2103546390A5045380644 @default.
• W2103546390 hasAuthorship W2103546390A5046939478 @default.
• W2103546390 hasAuthorship W2103546390A5060759473 @default.
• W2103546390 hasAuthorship W2103546390A5062388816 @default.
• W2103546390 hasAuthorship W2103546390A5066010864 @default.
• W2103546390 hasAuthorship W2103546390A5068970824 @default.
• W2103546390 hasAuthorship W2103546390A5070704228 @default.
• W2103546390 hasAuthorship W2103546390A5070860465 @default.
• W2103546390 hasAuthorship W2103546390A5072030442 @default.
• W2103546390 hasAuthorship W2103546390A5075821880 @default.
• W2103546390 hasAuthorship W2103546390A5081094525 @default.
• W2103546390 hasAuthorship W2103546390A5083634538 @default.
• W2103546390 hasConcept C121608353 @default.
• W2103546390 hasConcept C126322002 @default.
• W2103546390 hasConcept C159110408 @default.
• W2103546390 hasConcept C168563851 @default.
• W2103546390 hasConcept C2775860665 @default.
• W2103546390 hasConcept C2775930923 @default.
• W2103546390 hasConcept C2777176818 @default.
• W2103546390 hasConcept C2779951463 @default.
• W2103546390 hasConcept C2780723184 @default.
• W2103546390 hasConcept C530470458 @default.
• W2103546390 hasConcept C71924100 @default.
• W2103546390 hasConceptScore W2103546390C121608353 @default.
• W2103546390 hasConceptScore W2103546390C126322002 @default.
• W2103546390 hasConceptScore W2103546390C159110408 @default.
• W2103546390 hasConceptScore W2103546390C168563851 @default.
• W2103546390 hasConceptScore W2103546390C2775860665 @default.
• W2103546390 hasConceptScore W2103546390C2775930923 @default.
• W2103546390 hasConceptScore W2103546390C2777176818 @default.
• W2103546390 hasConceptScore W2103546390C2779951463 @default.
• W2103546390 hasConceptScore W2103546390C2780723184 @default.
• W2103546390 hasConceptScore W2103546390C530470458 @default.
• W2103546390 hasConceptScore W2103546390C71924100 @default.
• W2103546390 hasLocation W21035463901 @default.
• W2103546390 hasLocation W21035463902 @default.
• W2103546390 hasOpenAccess W2103546390 @default.
• W2103546390 hasPrimaryLocation W21035463901 @default.
• W2103546390 hasRelatedWork W1980928711 @default.
• W2103546390 hasRelatedWork W1984634588 @default.
• W2103546390 hasRelatedWork W1991252749 @default.
• W2103546390 hasRelatedWork W2046713166 @default.
• W2103546390 hasRelatedWork W2065475055 @default.
• W2103546390 hasRelatedWork W2081863978 @default.
• W2103546390 hasRelatedWork W2082323504 @default.
• W2103546390 hasRelatedWork W2164489340 @default.

• next